Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan

Table of Contents

EXECUTIVE SUMMARY

• Strategic scoping and focus
• Datamonitor insight into vaccines in emerging markets (Asia)
• Limitations
• Related reports
• Upcoming related reports

OVERVIEW OF THE FOUR MAIN ASIAN EMERGING MARKETS FOR VACCINES

• China and India offer a large, untapped demographic opportunity for vaccine makers
• The increasing wealth in Asia has led to the emergence of a promising private sector market for vaccines
• There is a promising opportunity for vaccines against endemic diseases in Asia
• Vaccination coverage and recommendations vary across the key emerging Asian markets
• There are significant differences regarding the general environment for vaccines in India, China, Taiwan and South Korea

INDIA

• Summary
• General characteristics
  • Demographics
  • Economics
  • Healthcare expenditure and access

• The Indian vaccines market
  • Historic development
  • Current market situation
  • Key stakeholders in India' s vaccination system

• Existing recommendations, coverage, available vaccines
  • Vaccination recommendations
  • Vaccination coverage
  • Available vaccines

• Regulatory process for vaccines
• Key vaccine players in India
  • General overview
  • Multinational corporations
  • Local vaccine players

• Key future target indications
• SWOT analysis of India as a target market for vaccine producers
• Best strategy for market penetration

CHINA

• Summary
• General characteristics
  • Demographics
  • Economics
  • Healthcare spend and access

• The Chinese vaccines market
  • Historic development
  • Current market situation
  • Key stakeholders in China' s vaccination system

• Existing recommendations, coverage, available vaccines
  • Vaccination recommendations
  • Vaccination coverage
  • Available vaccines

• Regulatory process for vaccines
• Key vaccine players in China
  • General overview
  • Multinational corporations
  • Local vaccine players

• Key future target indications
• SWOT analysis of China as a target market for vaccine producers
• Best strategy for market penetration

TAIWAN

• Summary
• General characteristics
  • Demographics
  • Economics
  • Healthcare spend and access

• The Taiwanese vaccines market
  • Historic development
  • Current market situation
  • Key stakeholders in Taiwan' s vaccination system

• Existing recommendations, coverage, available vaccines
  • Vaccination recommendations
  • Vaccination coverage
  • Available vaccines

• Regulatory process for vaccines
• Key vaccine players in Taiwan
  • General overview
  • Multinational corporations
  • Local vaccine players

• Key future target indications
• SWOT analysis of Taiwan as a target market for vaccine producers
• Best strategy for market penetration

SOUTH KOREA

• Summary
• General characteristics
  • Demographics
  • Economics
  • Healthcare spend and access

• The South Korean vaccines market
  • Historic development
  • Current market situation
  • Key stakeholders in South Korea' s vaccination system

• Existing recommendations, coverage, available vaccines
  • Vaccination recommendations
  • Vaccination coverage
  • Available vaccines

• Regulatory process for vaccines
• Key vaccine players in South Korea
  • General overview
  • Multinational corporations
  • Local vaccine players

• Key future target indications
• SWOT analysis of South Korea as a target market for vaccine producers
• Best strategy for market penetration

BIBLIOGRAPHY

• Literature

APPENDIX

• Contributing experts
  • Key opinion leaders
  • Conferences

• Report methodology

TABLES

• Table: Overview: Vaccines recommended as part of the national immunization schedule in India, China, Taiwan and South Korea, 2009
• Table: India: key economic indicators, 2006-08
• Table: India: healthcare expenditure indicators, 2006
• Table: India: key health system indicators, 2006
• Table: India: top 10 causes of mortality, 2004
• Table: India: estimated number of vaccine doses distributed for key indications, 2009
• Table: India: vaccination recommendations by the National Immunization Program (NIP) and the Indian Academy of Pediatrics ( IAP), 2009
• Table: India: top 10 vaccines by sales, 2008, as reported by MIDAS sales data, IMS Health, 2009
• Table: India: biotech turnover of key vaccine players, 2003/04 and 2004/05
• Table: India: position of the five key Western vaccine players, 2009
• Table: India: key local vaccine manufacturers, 2009
• Table: Serum Institute of India: human vaccine portfolio and pipeline overview, 2009
• Table: Serum Institute of India: key vaccine deals and alliances, 2009
• Table: Biological E: vaccine portfolio and pipeline overview, 2009
• Table: Biological E: key vaccine deals and alliances, 2009
• Table: Panacea Biotec: human vaccine portfolio and pipeline overview, 2009
• Table: Panacea Biotec: key vaccine deals and alliances, 2009
• Table: Shantha Biotechnics: human vaccine portfolio and pipeline overview, 2009
• Table: Shantha Biotechnics: key vaccine deals and alliances, 2009
• Table: Bharat Biotech: vaccine portfolio and pipeline overview, 2009
• Table: Bharat Biotech: key vaccine deals and alliances, 2009
• Table: Bio Med: vaccine portfolio and pipeline overview, 2009
• Table: Indian Immunologicals: human vaccine portfolio and pipeline overview, 2009
• Table: SWOT analysis of India as vaccine market, 2009
• Table: China: key economic indicators, 2006-08
• Table: China: healthcare expenditure indicators, 2006
• Table: China: key health system indicators, 2006
• Table: China: top 10 causes of mortality, 2004
• Table: China: estimated number of vaccine doses distributed for key indications, 2009
• Table: China: vaccination recommendations, 2009
• Table: China: top 10 vaccines by sales, 2008 , as reported by MIDAS sales data, IMS Health, 2009
• Table: China: position of the five key Western vaccine players, 2009
• Table: China: key local vaccine manufacturers, 2009
• Table: China National Biotec Group : human vaccine portfolio and pipeline overview, 2009
• Table: China National Biotec Group : key vaccine deals and alliances, 2009
• Table: Sinovac: human vaccine portfolio and pipeline overview, 2009
• Table: Sinovac: key vaccine deals and alliances, 2009
• Table: SWOT analysis of China as vaccine market, 2009
• Table: Taiwan: key economic indicators, 2006-08
• Table: Taiwan: healthcare expenditure indicators, 2005
• Table: Taiwan: top 10 causes of mortality, 2006
• Table: Taiwan: estimated number of vaccine doses distributed for key indications, 2009
• Table: Taiwan: vaccination recommendations, 2009
• Table: Taiwan: top 10 vaccines by sales, 2008 , as reported by MIDAS sales data, IMS Health, 2009
• Table: Taiwan: position of the five key Western vaccine players, 2009
• Table: ADImmune: human vaccine portfolio and pipeline overview, 2009
• Table: ADImmune: key vaccine deals and alliances, 2009
• Table: SWOT analysis of Taiwan as vaccine market, 2009
• Table: South Korea: key economic indicators, 2006-08
• Table: South Korea: healthcare expenditure indicators, 2006
• Table: South Korea: key health system indicators, 2006
• Table: South Korea: top 10 causes of mortality, 2004
• Table: South Korea: estimated number of vaccine doses distributed for key indications, 2009
• Table: South Korea: vaccination recommendations, 2009
• Table: South Korea: top 10 vaccines by sales, 2008 , as reported by MIDAS sales data, IMS Health, 2009
• Table: South Korea: classification of vaccines according to origin
• Table: South Korea: position of the five key Western vaccine players, 2009
• Table: South Korea: key local vaccine manufacturers, 2009
• Table: Korea Vaccine: human vaccine portfolio overview, 2009
• Table: SK Chemicals: human vaccine portfolio overview, 2009
• Table: SK Chemicals: key vaccine deals and alliances, 2009
• Table: Green Cross Korea: human vaccine portfolio and pipeline overview, 2009
• Table: Green Cross Korea: key vaccine deals and alliances, 2009
• Table: SWOT analysis of South Korea as vaccine market, 2009

FIGURES

• Figure: Overview: Total population size, India, China, Taiwan, South Korea, the US and the 5EU, 1994-2019
• Figure: Overview: Birth cohort size, India, China, Taiwan, South Korea, the US and the 5EU, 1994-2019
• Figure: Overview: Gross domestic product per capita, India, China, Taiwan, South Korea, the US and the 5EU, 1994-2019
• Figure: Overview: Healthcare spend per capita and private expenditure on health in India, China, Taiwan, South Korea, the US and the 5EU, 1994-2019
• Figure: Overview: Distribution of key endemic diseases in Asia
• Figure: Overview: Coverage for key vaccinations in India, China, Taiwan and South Korea, 2008
• Figure: Overview: Estimates of the market size for human vaccines in India, China, Taiwan and South Korea, 2009
• Figure: Overview: Key domestic vaccine players in India, China, Taiwan and South Korea, 2009
• Figure: Overview: Key vaccine market characteristics in India, China, Taiwan and South Korea, 2009
• Figure: India: overview of the vaccine landscape, 2009
• Figure: India: population growth, 1994-2019
• Figure: India: population spread by age group, 2009 versus 2019
• Figure: India: mortality of children <5 years of age, 1994-2019
• Figure: India: key stakeholders in administering Universal Immunization Program (UIP) vaccines, 2009
• Figure: India: National Immunization Program (NIP) vaccination schedule, 2009
• Figure: India: Indian Academy of Pediatrics ( IAP) vaccination schedule, 2009
• Figure: India: vaccination coverage, 2002-04 versus 2007-08
• Figure: India: vaccine sales by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: India: vaccine volume use by Anatomical Therapeutic Chemical (ATC) class , 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: India: market share of total vaccine sales for local and multinational vaccine manufacturers, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: India: market share of total vaccine sales by company, 2008, as reported by MIDAS sales data, IMS Health, 2009
• Figure: India: key future target vaccine indications, 2009
• Figure: China: overview of the vaccine landscape, 2009
• Figure: China: population growth, 1994-2019
• Figure: China: population spread by age group, 2009 versus 2019
• Figure: China: mortality of children <5 years of age, 1994-2019
• Figure: China: vaccination schedule, 2009
• Figure: China: vaccination coverage, 2004-08
• Figure: China: vaccine sales by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: China: vaccine volume use by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: China: market share of total vaccine sales for local and multinational vaccine manufacturers, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: China: market share of total vaccine sales by company, 2008, as reported by MIDAS sales data, IMS Health, 2009
• Figure: China National Biotec Group: organization structure
• Figure: China: key future target vaccine indications, 2009
• Figure: Taiwan: overview of the vaccine landscape, 2009
• Figure: Taiwan: development of population size, 1994-2019
• Figure: Taiwan: population spread by age group, 2009 versus 2019
• Figure: Taiwan: mortality of children <5 years of age, 1994-2019
• Figure: Taiwan: vaccination schedule, 2009
• Figure: Taiwan: vaccination coverage, 2009
• Figure: Taiwan: vaccine sales by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: Taiwan: vaccine volume use by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: Taiwan: market share of total vaccine sales for local and multinational vaccine manufacturers, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: Taiwan: market share of total vaccine sales by company, 2008, as reported by MIDAS sales data, IMS Health, 2009
• Figure: Taiwan: key future target vaccine indications, 2009
• Figure: South Korea: overview of the vaccine landscape, 2009
• Figure: South Korea: population growth, 1994-2019
• Figure: South Korea: population spread by age group, 2009 versus 2019
• Figure: South Korea: mortality of children <5 years of age, 1994-2019
• Figure: South Korea: vaccination schedule, 2009
• Figure: South Korea: vaccination coverage, 2004-08
• Figure: South Korea: vaccine sales by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: South Korea: vaccine volume use by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: South Korea: market share of total vaccine sales for local and multinational vaccine manufacturers, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
• Figure: South Korea: market share of total vaccine sales by company, 2008, as reported by MIDAS sales data, IMS Health, 2009
• Figure: South Korea: vaccine imports versus local manufacturing, 2009
• Figure: South Korea: key future target vaccine indications, 2009